Human Anti centriole and centrosome antibody IgG ELISA kit |
E01A0698-192T |
BlueGene |
192 tests |
EUR 1524 |
|
Description: A competitive ELISA for quantitative measurement of Human Anti centriole and centrosome antibody IgG in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species. |
Human IgG antibody Laboratories manufactures the lee biosolution reagents distributed by Genprice. The Lee Biosolution reagent is RUO (Research Use Only) to test human serum or cell culture lab samples. To purchase these products, for the MSDS, Data Sheet, protocol, storage conditions/temperature or for the concentration, please contact Lee Biosolutions Ltd.. Other Lee products are available in stock. Specificity: Lee Category: Biosolution
Human true insulin,TI ELISA Kit |
SunredBio |
96 tests |
EUR 528 |
|
Description: A quantitative ELISA kit for measuring Human in samples from biological fluids. |
Human true insulin,TI ELISA Kit |
ChemNorm |
96T |
EUR 567.6 |
Chemicals information
LEE011 |
A8641-25 |
ApexBio |
25 mg |
EUR 338.4 |
Description: LEE011 (NVP-LEE011) is a highly specific inhibitor of CDK4/CDK6 and functions via decreasing in phosphorylated RB and FOXM1 [1]. When tested with 17 human neuroblastoma cell lines, 12 of them were sensitive to LEE011 treatment with mean IC50=306±68 nM [2]. |
LEE011 |
A8641-5 |
ApexBio |
5 mg |
EUR 170.4 |
Description: LEE011 (NVP-LEE011) is a highly specific inhibitor of CDK4/CDK6 and functions via decreasing in phosphorylated RB and FOXM1 [1]. When tested with 17 human neuroblastoma cell lines, 12 of them were sensitive to LEE011 treatment with mean IC50=306±68 nM [2]. |
LEE011 |
A8641-5.1 |
ApexBio |
10 mM (in 1mL DMSO) |
EUR 181.2 |
Description: LEE011 (NVP-LEE011) is a highly specific inhibitor of CDK4/CDK6 and functions via decreasing in phosphorylated RB and FOXM1 [1]. When tested with 17 human neuroblastoma cell lines, 12 of them were sensitive to LEE011 treatment with mean IC50=306±68 nM [2]. |
LEE011 |
A8641-50 |
ApexBio |
50 mg |
EUR 408 |
Description: LEE011 (NVP-LEE011) is a highly specific inhibitor of CDK4/CDK6 and functions via decreasing in phosphorylated RB and FOXM1 [1]. When tested with 17 human neuroblastoma cell lines, 12 of them were sensitive to LEE011 treatment with mean IC50=306±68 nM [2]. |
LEE011 succinate |
B1084-10 |
ApexBio |
10 mg |
EUR 200.4 |
Description: LEE011 succinate is an orally available cyclin-dependent kinase (CDK) inhibitor targeting cyclin D1/CDK4 and cyclin D3/CDK6 cell cycle pathway, with potential antineoplastic activity. |
LEE011 succinate |
B1084-100 |
ApexBio |
100 mg |
EUR 420 |
Description: LEE011 succinate is an orally available cyclin-dependent kinase (CDK) inhibitor targeting cyclin D1/CDK4 and cyclin D3/CDK6 cell cycle pathway, with potential antineoplastic activity. |
LEE011 succinate |
B1084-200 |
ApexBio |
200 mg |
EUR 640.8 |
Description: LEE011 succinate is an orally available cyclin-dependent kinase (CDK) inhibitor targeting cyclin D1/CDK4 and cyclin D3/CDK6 cell cycle pathway, with potential antineoplastic activity. |
LEE011 succinate |
B1084-5 |
ApexBio |
5 mg |
EUR 160.8 |
Description: LEE011 succinate is an orally available cyclin-dependent kinase (CDK) inhibitor targeting cyclin D1/CDK4 and cyclin D3/CDK6 cell cycle pathway, with potential antineoplastic activity. |
LEE011 succinate |
B1084-5.1 |
ApexBio |
10 mM (in 1mL DMSO) |
EUR 192 |
Description: LEE011 succinate is an orally available cyclin-dependent kinase (CDK) inhibitor targeting cyclin D1/CDK4 and cyclin D3/CDK6 cell cycle pathway, with potential antineoplastic activity. |
LEE011 succinate |
B1084-50 |
ApexBio |
50 mg |
EUR 300 |
Description: LEE011 succinate is an orally available cyclin-dependent kinase (CDK) inhibitor targeting cyclin D1/CDK4 and cyclin D3/CDK6 cell cycle pathway, with potential antineoplastic activity. |
LEE011 succinate |
B1084-500 |
ApexBio |
500 mg |
EUR 1101.6 |
Description: LEE011 succinate is an orally available cyclin-dependent kinase (CDK) inhibitor targeting cyclin D1/CDK4 and cyclin D3/CDK6 cell cycle pathway, with potential antineoplastic activity. |
Ribociclib (LEE011) |
9481-25 |
Biovision |
each |
EUR 548.4 |
Ribociclib (LEE011) |
9481-5 |
Biovision |
each |
EUR 183.6 |